CVKD
Income statement / Annual
Last year (2024), Cadrenal Therapeutics, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Cadrenal Therapeutics, Inc. Common Stock's net income was -$10.65 M.
See Cadrenal Therapeutics, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$1.27 K
|
| Gross Profit |
$0.00
|
$0.00
|
-$1.27 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$4.21 M
|
$4.08 M
|
$392.86 K
|
| General & Administrative Expenses |
$6.75 M
|
$3.55 M
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.75 M
|
$3.55 M
|
$2.31 M
|
| Other Expenses |
$1.88 K
|
$1.98 K
|
$0.00
|
| Operating Expenses |
$10.96 M
|
$7.63 M
|
$2.70 M
|
| Cost And Expenses |
$10.96 M
|
$7.63 M
|
$2.70 M
|
| Interest Income |
$309.25 K
|
$249.09 K
|
$0.00
|
| Interest Expense |
$0.00
|
$17.10 K
|
$107.11 K
|
| Depreciation & Amortization |
$1.88 K
|
$1.98 K
|
$1.27 K
|
| EBITDA |
-$10.65 M |
-$8.34 M |
-$6.61 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$309.25 K
|
-$724.24 K
|
-$4.01 M
|
| Income Before Tax |
-$10.65 M
|
-$8.36 M
|
-$6.71 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$10.65 M
|
-$8.36 M
|
-$6.71 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-8.73 |
-9.63 |
-8.66 |
| EPS Diluted |
-8.73 |
-9.63 |
-8.66 |
| Weighted Average Shares Out |
$1.22 M
|
$868.18 K
|
$775.64 K
|
| Weighted Average Shares Out Diluted |
$1.22 M
|
$868.18 K
|
$775.64 K
|
| Link |
|
|
|
